(WGS) GeneDx Holdings - Ratings and Ratios
Diagnostic Testing, Exome Sequencing, Genome Sequencing, AI Analytics
WGS EPS (Earnings per Share)
WGS Revenue
Description: WGS GeneDx Holdings
GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company specializing in genetic testing services, with a primary focus on pediatric and rare disease diagnostics through whole exome and genome sequencing. The company also offers data and information services, and is developing an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
To evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue. Given the companys focus on genetic testing services, its likely that revenue growth is driven by the increasing demand for genomics-based diagnostics. A review of the companys financials would reveal whether GeneDx is able to maintain a high gross margin, indicating a strong pricing power and efficient cost structure.
From a trading perspective, we can analyze the stocks price action and identify potential trading opportunities. The stock has shown significant volatility, with an Average True Range (ATR) of 4.30, representing a 4.24% daily price movement. This suggests that traders may be able to capitalize on large price swings. Additionally, the stocks Relative Strength Index (RSI) and Bollinger Bands could be used to identify overbought or oversold conditions, and potential breakouts or mean reversion opportunities.
To further assess the companys valuation, we can examine metrics such as the Price-to-Sales (P/S) ratio, Enterprise Value-to-EBITDA (EV/EBITDA) ratio, and the companys cash flow generation. A comparison of these metrics to industry peers would provide insight into whether GeneDx is undervalued or overvalued relative to its competitors. With a Market Cap of $2.93B and a P/E ratio of 1274.38, the companys valuation appears to be stretched, suggesting that investors have high expectations for future growth.
WGS Stock Overview
| Market Cap in USD | 3,742m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2020-11-04 |
WGS Stock Ratings
| Growth Rating | 50.2% |
| Fundamental | 50.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 173% |
| Analyst Rating | 4.67 of 5 |
WGS Dividends
Currently no dividends paidWGS Growth Ratios
| Growth Correlation 3m | 87.1% |
| Growth Correlation 12m | 61.1% |
| Growth Correlation 5y | -48.4% |
| CAGR 5y | 53.55% |
| CAGR/Max DD 3y | 0.56 |
| CAGR/Mean DD 3y | 1.23 |
| Sharpe Ratio 12m | -0.46 |
| Alpha | 259.54 |
| Beta | 0.257 |
| Volatility | 76.80% |
| Current Volume | 311.9k |
| Average Volume 20d | 469.9k |
| Stop Loss | 116.2 (-6.3%) |
| Signal | -0.73 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (1.41m TTM) > 0 and > 6% of Revenue (6% = 21.7m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 49.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 36.83% (prev 38.54%; Δ -1.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 13.0m > Net Income 1.41m (YES >=105%, WARN >=100%) |
| Net Debt (-11.4m) to EBITDA (22.8m) ratio: -0.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.8m) change vs 12m ago 11.78% (target <= -2.0% for YES) |
| Gross Margin 67.18% (prev 50.22%; Δ 16.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 84.96% (prev 62.62%; Δ 22.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.00 (EBITDA TTM 22.8m / Interest Expense TTM 3.00m) >= 6 (WARN >= 3) |
Altman Z'' -15.12
| (A) 0.29 = (Total Current Assets 204.8m - Total Current Liabilities 71.4m) / Total Assets 463.9m |
| (B) -2.91 = Retained Earnings (Balance) -1.35b / Total Assets 463.9m |
| warn (B) unusual magnitude: -2.91 — check mapping/units |
| (C) 0.01 = EBIT TTM 2.99m / Avg Total Assets 426.5m |
| (D) -7.22 = Book Value of Equity -1.35b / Total Liabilities 186.7m |
| Total Rating: -15.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 50.36
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 0.16% = 0.08 |
| 3. FCF Margin 1.60% = 0.40 |
| 4. Debt/Equity 0.20 = 2.48 |
| 5. Debt/Ebitda 2.40 = -0.77 |
| 6. ROIC - WACC -5.90% = -7.38 |
| 7. RoE 0.57% = 0.05 |
| 8. Rev. Trend 65.41% = 3.27 |
| 9. Rev. CAGR 7.94% = 0.99 |
| 10. EPS Trend 89.37% = 2.23 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of WGS shares?
Over the past week, the price has changed by -6.48%, over one month by +6.48%, over three months by +86.76% and over the past year by +224.73%.
Is GeneDx Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WGS is around 111.85 USD . This means that WGS is currently overvalued and has a potential downside of -9.76%.
Is WGS a buy, sell or hold?
- Strong Buy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the WGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 121.3 | -2.2% |
| Analysts Target Price | 121.3 | -2.2% |
| ValueRay Target Price | 122.9 | -0.8% |
Last update: 2025-09-06 05:04
WGS Fundamental Data Overview
CCE Cash And Equivalents = 134.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 1628.25
P/S = 10.3275
P/B = 13.5021
Beta = 2.097
Revenue TTM = 362.3m USD
EBIT TTM = 2.99m USD
EBITDA TTM = 22.8m USD
Long Term Debt = 51.7m USD (from longTermDebt, last quarter)
Short Term Debt = 3.08m USD (from shortTermDebt, last quarter)
Debt = 54.8m USD (Calculated: Short Term 3.08m + Long Term 51.7m)
Net Debt = -11.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.66b USD (3.74b + Debt 54.8m - CCE 134.6m)
Interest Coverage Ratio = 1.00 (Ebit TTM 2.99m / Interest Expense TTM 3.00m)
FCF Yield = 0.16% (FCF TTM 5.81m / Enterprise Value 3.66b)
FCF Margin = 1.60% (FCF TTM 5.81m / Revenue TTM 362.3m)
Net Margin = 0.39% (Net Income TTM 1.41m / Revenue TTM 362.3m)
Gross Margin = 67.18% ((Revenue TTM 362.3m - Cost of Revenue TTM 118.9m) / Revenue TTM)
Tobins Q-Ratio = -2.72 (set to none) (Enterprise Value 3.66b / Book Value Of Equity -1.35b)
Interest Expense / Debt = 1.49% (Interest Expense 817.0k / Debt 54.8m)
Taxrate = 2.33% (246.0k / 10.6m)
NOPAT = 2.92m (EBIT 2.99m * (1 - 2.33%))
Current Ratio = 2.87 (Total Current Assets 204.8m / Total Current Liabilities 71.4m)
Debt / Equity = 0.20 (Debt 54.8m / last Quarter total Stockholder Equity 277.1m)
Debt / EBITDA = 2.40 (Net Debt -11.4m / EBITDA 22.8m)
Debt / FCF = 9.43 (Debt 54.8m / FCF TTM 5.81m)
Total Stockholder Equity = 246.1m (last 4 quarters mean)
RoA = 0.30% (Net Income 1.41m, Total Assets 463.9m )
RoE = 0.57% (Net Income TTM 1.41m / Total Stockholder Equity 246.1m)
RoCE = 1.00% (Ebit 2.99m / (Equity 246.1m + L.T.Debt 51.7m))
RoIC = 0.98% (NOPAT 2.92m / Invested Capital 297.9m)
WACC = 6.88% (E(3.74b)/V(3.80b) * Re(6.96%)) + (D(54.8m)/V(3.80b) * Rd(1.49%) * (1-Tc(0.02)))
Shares Correlation 3-Years: 96.97 | Cagr: 8.99%
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈5.81m ; Y1≈3.81m ; Y5≈1.74m
Fair Price DCF = 1.19 (DCF Value 34.3m / Shares Outstanding 28.7m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 65.41 | Revenue CAGR: 7.94%
Rev Growth-of-Growth: 38.34
EPS Correlation: 89.37 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 23.45
Additional Sources for WGS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle